Capricor Therapeutics (CAPR) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to -$24.6 million.
- Capricor Therapeutics' Net Income towards Common Stockholders fell 9567.63% to -$24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.5 million, marking a year-over-year decrease of 6825.08%. This contributed to the annual value of -$40.4 million for FY2024, which is 8059.67% down from last year.
- According to the latest figures from Q3 2025, Capricor Therapeutics' Net Income towards Common Stockholders is -$24.6 million, which was down 9567.63% from -$25.9 million recorded in Q2 2025.
- Capricor Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$829093.0 for Q4 2023, and its period low was -$25.9 million during Q2 2025.
- In the last 5 years, Capricor Therapeutics' Net Income towards Common Stockholders had a median value of -$7.2 million in 2023 and averaged -$9.3 million.
- As far as peak fluctuations go, Capricor Therapeutics' Net Income towards Common Stockholders soared by 8921.39% in 2023, and later tumbled by 74565.53% in 2024.
- Over the past 5 years, Capricor Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$6.4 million in 2021, then fell by 20.79% to -$7.7 million in 2022, then skyrocketed by 89.21% to -$829093.0 in 2023, then tumbled by 745.66% to -$7.0 million in 2024, then tumbled by 250.44% to -$24.6 million in 2025.
- Its last three reported values are -$24.6 million in Q3 2025, -$25.9 million for Q2 2025, and -$7.0 million during Q4 2024.